Septerna, Inc. Common Stock (SEPN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Septerna, Inc. Common Stock (SEPN) Stock Forecast
Analysts expect Septerna, Inc. Common Stock (SEPN) to earn -$1.20 per share in the fiscal year ending Dec 31, 2026, on revenue of $89.17M. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.90, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 9 | 90.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 22.9%.
- Fiscal year ending Dec 31, 2026
- -$1.20
- EPS consensus, revenue $89.17M
- Fiscal year ending Dec 31, 2027
- -$1.91
- EPS consensus, revenue $68.73M
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.20 | -$1.36 to -$1.03 | 3 | $89.17M | $72.20M to $100.00M | 5 |
| Dec 31, 2027 | -$1.91 | -$2.64 to -$1.34 | 4 | $68.73M | N/A | 9 |
Quarterly Estimates
The EPS consensus falls from -$0.46 for the quarter ending Dec 31, 2026 to -$0.50 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.46 | -$0.93 to -$0.21 | 12 | $22.03M | N/A | 12 |
| Mar 31, 2027 | -$0.50 | -$0.50 to -$0.50 | 1 | $11.05M | N/A | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 2 |
| Fiscal year ending Dec 31, 2027 | 2 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.18.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.20 | -$1.19 | -$1.19 | -$1.19 | -$1.18 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.91 | -$1.94 | -$1.94 | -$1.94 | -$1.83 | N/A |
| Quarter ending Mar 31, 2027 | -$0.50 | -$0.37 | -$0.37 | -$0.37 | -$0.31 | N/A |
Frequently Asked Questions About SEPN
What is the SEPN stock forecast?
Consensus analyst estimates put Septerna, Inc. Common Stock's EPS at -$1.20 for the fiscal year ending Dec 31, 2026, on revenue of $89.17M. The consensus rating from 10 analysts is Buy.
How do analysts rate SEPN stock?
Of 10 analysts covering Septerna, Inc. Common Stock, 1 rates it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SEPN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.20, with estimates from -$1.36 to -$1.03 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.91, with estimates from -$2.64 to -$1.34 from 4 analysts.
What revenue do analysts expect from Septerna, Inc. Common Stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $89.17M, with estimates from $72.20M to $100.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $68.73M.
How many analysts cover SEPN?
10 analysts rate Septerna, Inc. Common Stock stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SEPN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors